Kamada Net Change in Intangible Assets 2012-2025 | KMDA

Kamada net change in intangible assets from 2012 to 2025. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.

Kamada Net Change in Intangible Assets 2012-2025 | KMDA

Kamada net change in intangible assets from 2012 to 2025. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$247.8B
Amgen (AMGN)$154.9B
Gilead Sciences (GILD)$140.2B
Vertex Pharmaceuticals (VRTX)$100.3B
Bristol Myers Squibb (BMY)$96B
GSK (GSK)$80.8B
CSL (CSLLY)$67.1B
Regeneron Pharmaceuticals (REGN)$61.5B
Alnylam Pharmaceuticals (ALNY)$58.5B
Argenex SE (ARGX)$43.6B
Insmed (INSM)$28.8B
BioNTech SE (BNTX)$24B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$19.4B
Incyte (INCY)$16.5B
Genmab (GNMSF)$16.5B
Genmab (GMAB)$16B
Illumina (ILMN)$15.4B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.3B
Exelixis (EXEL)$10.1B
Moderna (MRNA)$9.4B
Verona Pharma American Depositary Share (VRNA)$9.2B
Exact Sciences (EXAS)$9B
Bio-Techne Corp (TECH)$8.6B
Halozyme Therapeutics (HALO)$8.6B
Guardant Health (GH)$8.4B
Blueprint Medicines (BPMC)$8.3B